Paget's disease-a VDR coactivator disease? - PubMed (original) (raw)
Review
Paget's disease-a VDR coactivator disease?
Noriyoshi Kurihara et al. J Steroid Biochem Mol Biol. 2004 May.
Abstract
Paget's disease is the most exaggerated example of bone remodeling with increased osteoclastic bone resorption followed by excessive bone formation. One of the earliest findings in our studies of Paget's disease is that pagetic osteoclast (OCL) precursors are hyper-responsive to 1,25-(OH)(2)D(3) and form OCL at concentrations of 1,25-(OH)(2)D(3) that are physiologic rather than pharmacologic. The increased responsivity to 1,25-(OH)(2)D(3) is not due to increased levels of the Vitamin D receptor (VDR) or to increased infinity of 1,25-(OH)(2)D(3) for VDR. We have recently shown using GST-VDR chimeric protein pull-down assays that TAF(II)-17, a member of the TAF(II)-D transcription complex, is increased in OCL precursors from patients with Paget's disease compared to normals. We further showed that TAF(II)-17 can enhance VDR mediated gene transcription and allow formation of the transcription complex at very low levels of 1,25-(OH)(2)D(3). In addition, coactivators of VDR including CPB300 and DRIP205 are also increased in OCL precursors from Paget's patients. These data suggest that the enhanced sensitivity of OCL precursors for 1,25-(OH)(2)D(3) in Paget's disease results from increased expression of coactivators of VDR and suggest that part of the pathophysiology underlying OCL formation in Paget's disease may result from enhanced expression of VDR coactivators.
Similar articles
- Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease.
Kurihara N, Reddy SV, Araki N, Ishizuka S, Ozono K, Cornish J, Cundy T, Singer FR, Roodman GD. Kurihara N, et al. J Bone Miner Res. 2004 Jul;19(7):1154-64. doi: 10.1359/JBMR.040312. Epub 2004 Mar 15. J Bone Miner Res. 2004. PMID: 15176999 - 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.
Menaa C, Barsony J, Reddy SV, Cornish J, Cundy T, Roodman GD. Menaa C, et al. J Bone Miner Res. 2000 Feb;15(2):228-36. doi: 10.1359/jbmr.2000.15.2.228. J Bone Miner Res. 2000. PMID: 10703924 - Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells.
Ishizuka S, Kurihara N, Miura D, Takenouchi K, Cornish J, Cundy T, Reddy SV, Roodman GD. Ishizuka S, et al. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):331-4. doi: 10.1016/j.jsbmb.2004.03.025. J Steroid Biochem Mol Biol. 2004. PMID: 15225795 - Experimental models of Paget's disease.
Kurihara N, Zhou H, Reddy SV, Garcia Palacios V, Subler MA, Dempster DW, Windle JJ, Roodman GD. Kurihara N, et al. J Bone Miner Res. 2006 Dec;21 Suppl 2:P55-7. doi: 10.1359/jbmr.06s210. J Bone Miner Res. 2006. PMID: 17229020 Review. - Etiology of Paget's disease and osteoclast abnormalities.
Reddy SV. Reddy SV. J Cell Biochem. 2004 Nov 1;93(4):688-96. doi: 10.1002/jcb.20256. J Cell Biochem. 2004. PMID: 15389972 Review.
Cited by
- TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation.
Sun Q, Sammut B, Wang FM, Kurihara N, Windle JJ, Roodman GD, Galson DL. Sun Q, et al. J Bone Miner Res. 2014 Jan;29(1):90-102. doi: 10.1002/jbmr.2026. J Bone Miner Res. 2014. PMID: 23794264 Free PMC article. - On the mechanism underlying (23S)-25-dehydro-1alpha(OH)-vitamin D3-26,23-lactone antagonism of hVDRwt gene activation and its switch to a superagonist.
Mizwicki MT, Bula CM, Mahinthichaichan P, Henry HL, Ishizuka S, Norman AW. Mizwicki MT, et al. J Biol Chem. 2009 Dec 25;284(52):36292-36301. doi: 10.1074/jbc.M109.042069. Epub 2009 Sep 28. J Biol Chem. 2009. PMID: 19801650 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous